Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Mar;82(5):1547–1551. doi: 10.1073/pnas.82.5.1547

Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

M Mason-Garcia, S Vigh, A M Comaru-Schally, T W Redding, A Somogyvari-Vigh, J Horvath, A V Schally
PMCID: PMC397301  PMID: 3156381

Abstract

A sensitive and specific radioimmunoassay for [6-D-tryptophan]luteinizing hormone-releasing hormone [( D-Trp6]LH-RH) was developed and used for following the rate of liberation of [D-Trp6]LH-RH from a long-acting delivery system based on a microcapsule formulation. Rabbit antibodies were generated against [D-Trp6]LH-RH conjugated to bovine serum albumin with glutaraldehyde. Crossreactivity with LH-RH was less than 1%; there was no significant crossreactivity with other peptides. The minimal detectable dose of [D-Trp6]LH-RH was 2 pg per tube. Intra- and interassay coefficients of variation were 8% and 10%, respectively. The radioimmunoassay was suitable for direct determination of [D-Trp6]LH-RH in serum, permitting the study of blood levels of the analog after single injections into normal men and after once-a-month administration of microcapsules to rats. In men, 90 min after subcutaneous injection of 250 micrograms of the peptide, serum [D-Trp6]LH-RH rose to 6-12 ng/ml. Luteinizing hormone was increased 90 min and 24 hr after the administration of the analog. Several batches of microcapsules were tested in rats and the rate of release of [D-Trp6]LH-RH was followed. The improved batch of microcapsules of [D-Trp6]LH-RH increased serum concentrations of the analog for 30 days or longer after intramuscular injection. This was accompanied by suppression of testosterone levels for more than 30 days. This radioimmunoassay should be of value for monitoring [D-Trp6]LH-RH during long-term therapy.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barron J. L., Millar R. P., Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1982 Jun;54(6):1169–1173. doi: 10.1210/jcem-54-6-1169. [DOI] [PubMed] [Google Scholar]
  2. Comaru-Schally A. M., Ramalho A., Leitao P. R., Schally A. V. Clearance of lung metastases of prostate carcinoma after treatment with LH-RH agonist. Lancet. 1984 Aug 4;2(8397):281–282. doi: 10.1016/s0140-6736(84)90319-2. [DOI] [PubMed] [Google Scholar]
  3. Corbin A. From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med. 1982 Jan-Feb;55(1):27–47. [PMC free article] [PubMed] [Google Scholar]
  4. Evans R. M., Doelle G. C., Lindner J., Bradley V., Rabin D. A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. J Clin Invest. 1984 Jan;73(1):262–266. doi: 10.1172/JCI111200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Heber D., Odell W. D., Schedewie H., Wolfsen A. R. Improved iodination of peptides for radioimmunoassay and membrane radioreceptor assay. Clin Chem. 1978 May;24(5):796–799. [PubMed] [Google Scholar]
  6. Laron Z., Kauli R., Zeev Z. B., Comaru-Schally A. M., Schally A. V. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet. 1981 Oct 31;2(8253):955–956. doi: 10.1016/s0140-6736(81)91155-7. [DOI] [PubMed] [Google Scholar]
  7. Redding T. W., Schally A. V., Tice T. R., Meyers W. E. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5845–5848. doi: 10.1073/pnas.81.18.5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Reichlin M., Schnure J. J., Vance V. K. Induction of antibodies to porcine ACTH in rabbits with nonsteroidogenic polymers of BSA and ACTH. Proc Soc Exp Biol Med. 1968 Jun;128(2):347–350. doi: 10.3181/00379727-128-33011. [DOI] [PubMed] [Google Scholar]
  9. Sandow J., Von Rechenberg W., Jerzabek G., Stoll W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril. 1978 Aug;30(2):205–209. doi: 10.1016/s0015-0282(16)43461-8. [DOI] [PubMed] [Google Scholar]
  10. Schally A. V., Comaru-Schally A. M., Redding T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med. 1984 Mar;175(3):259–281. doi: 10.3181/00379727-175-41797. [DOI] [PubMed] [Google Scholar]
  11. Schally A. V., Coy D. H., Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318–324. doi: 10.1002/j.1879-3479.1980.tb00507.x. [DOI] [PubMed] [Google Scholar]
  12. Schally A. V., Redding T. W., Comaru-Schally A. M. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep. 1984 Jan;68(1):281–289. [PubMed] [Google Scholar]
  13. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Walker K. J., Nicholson R. I., Turkes A. O., Turkes A., Griffiths K., Robinson M., Crispin Z., Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet. 1983 Aug 20;2(8347):413–415. doi: 10.1016/s0140-6736(83)90386-0. [DOI] [PubMed] [Google Scholar]
  15. Waxman J. H., Wass J. A., Hendry W. F., Whitfield H. N., Besser G. M., Malpas J. S., Oliver R. T. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. doi: 10.1136/bmj.286.6374.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES